Lemtrada

Alemtuzumab, the active ingredient in Lemtrada, is a monoclonal antibody presented as a 12 mg/mL solution for injection for intravenous use. It is indicated for the treatment of relapsing‑remitting multiple sclerosis in adult patients, helping to reduce disease activity and relapse frequency.

GNH USA supplies Lemtrada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory‑aligned distribution, and cold‑chain logistics for this specialized immunosuppressive therapy.

Lemtrada (alemtuzumab) is used in the management of autoimmune demyelinating disease, specifically targeting the immune mechanisms of multiple sclerosis.

Relapsing‑remitting multiple sclerosis: reduces relapse rate and slows progression of disability in adult patients.

Lemtrada may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Infusion‑related reactions (fever, chills, rash) - Headache - Nausea - Upper respiratory tract infection - Fatigue

Serious or Rare Side Effects: - Autoimmune thyroid disease (hyper‑ or hypothyroidism) - Immune thrombocytopenic purpura - Nephropathy (glomerulonephritis) - Severe infections (herpes, opportunistic) - Cytopenias (neutropenia, anemia) - Malignancies (skin cancers, lymphomas)

Before initiating Lemtrada, several safety considerations should be addressed. - Baseline blood counts: obtain complete blood count and differential prior to therapy. - Thyroid function: assess TSH and free T4 before and during treatment. - Infection screening: test for hepatitis B, C, HIV and tuberculosis; treat active infections before infusion. - Vaccination: avoid live vaccines during and for several months after treatment. - Pregnancy and lactation: drug category unknown; avoid use in pregnant or nursing women unless benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lemtrada can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Live attenuated vaccines: may cause uncontrolled infection; avoid concurrent use. - Other immunosuppressants (e.g., azathioprine, cyclophosphamide): increase risk of severe infections. - Antiviral prophylaxis when not indicated: may heighten toxicity.

Moderate Interactions (Monitor Closely): - Antithyroid drugs: may mask emerging thyroid autoimmunity; monitor thyroid labs. - Anticoagulants: potential for increased bleeding if thrombocytopenia develops; check coagulation parameters. - Concomitant biologics: overlapping immunosuppression may require dose adjustment and close monitoring.